The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112 and who have exited an antecedent study.
Age range
18 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of Participants with Adverse Events (AEs)
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Intraocular Pressure (IOP)
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Abnormal Slit Lamp Examination
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Lens Opacity Grading
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Anterior Chamber and Vitreous Inflammation
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Indirect Ophthalmoscopy
Timeframe: Up to 5 years